Circulating EGFL7 distinguishes between IUGR and PE: an observational case-control study

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biomarker Discovery

Background:

• Intrauterine growth restriction (IUGR) and preeclampsia (PE) share placental origins but PE is a systemic disorder.
• Early diagnosis of IUGR and PE is crucial for optimizing maternal and fetal outcomes.
• Identifying specific biomarkers can differentiate these conditions and guide management.

Purpose of the Study:

• To investigate if circulating Epidermal Growth Factor-Like domain 7 (EGFL7) levels can differentiate between isolated IUGR and PE.
• To compare EGFL7 levels in pregnant women with IUGR, PE, and healthy controls.

Main Methods:

• A case-control study involving 116 women (controls, IUGR, PE) was conducted.
• Maternal plasma levels of EGFL7 and other angiogenic factors were measured using ELISA at various gestational ages.
• Statistical analysis compared EGFL7 levels across different study groups.

Main Results:

• Significantly higher EGFL7 levels were observed in early-onset PE (e-PE) compared to controls and isolated IUGR between 22-25 weeks gestation.
• Elevated EGFL7 levels persisted in e-PE compared to IUGR between 26-34 weeks.
• At term, EGFL7 levels were similar between IUGR and late-onset PE (l-PE).
• Placental growth factor (PlGF) was decreased, while soluble fms-like tyrosine kinase-1 (sFLT-1) and soluble endoglin (sENG) were increased in both IUGR and PE.

Conclusions:

• Circulating EGFL7 levels show significant potential to discriminate between isolated IUGR and PE.
• EGFL7 may serve as a valuable biomarker for early diagnosis and management of PE.
• Further research is warranted to explore the clinical utility of EGFL7 in obstetric practice.